Quinagolide

CHEMBL2218861 Phase 4 Onaylandı Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
395.6 g/mol
LogP
3.1
Phase
4

Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist that acts on lactotroph D2 receptors in the pituitary gland to suppress prolactin secretion. It is used for the treatment of hyperprolactinemia including prolactin-secreting adenomas, and has been investigated for its anti-angiogenic properties in endometriosis.

Moleküler Ağırlık

395,6000 g/mol

LogP

3,10

TPSA

81,30 Ų

Lipinski RO5

Geçer

Terapötik Alanlar

Etki Mekanizması

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanizma

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

2D Yapı

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCN1CC(NS(=O)(=O)N(CC)CC)CC2Cc3c(O)cccc3CC21

InChI

InChI=1S/C20H33N3O3S/c1-4-10-22-14-17(21-27(25,26)23(5-2)6-3)11-16-12-18-15(13-19(16)22)8-7-9-20(18)24/h7-9,16-17,19,21,24H,4-6,10-14H2,1-3H3

Molecular Formula

C20H33N3O3S

HBD / HBA

2 / 6

Döndürülebilir Bağlar

7

Ağır Atomlar

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Sıkça Sorulan Sorular

Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist that acts on lactotroph D2 receptors in the pituitary gland to suppress prolactin secretion. It is used for the treatment of hyperprolactinemia including prolactin-secreting adenomas, and has been investigated for its anti-angiogenic properties in endometriosis.

Binds to and activates its target receptor, mimicking the action of the endogenous ligand to produce a specific physiological response.

Yes, Quinagolide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2218861. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3086401. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

Tıbbi Sorumluluk Reddi

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.